IDiyas

For the Inventor, By the Inventor

Penzberg, Germany

Konrad Honold

USPTO Granted Patents = 24 


Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 110(Granted Patents)


Company Filing History:

goldMedal13 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents
silverMedal9 out of 480 
 
Roche Diagnostics Gmbh
 patents
bronzeMedal1 out of 1,164 
 
Boehringer Mannheim Gmbh
 patents
4. 1 out of 832,680 
Other
 patents

Years Active: 1999-2011

where 'Filed Patents' based on already Granted Patents

24 patents (USPTO):
1. 8067599 - Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors (2011-11-29),
2. 8058283 - 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors (2011-11-15),
3. 7786113 - Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents (2010-08-31),
4. 7776878 - Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents (2010-08-17),
5. 7655651 - Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents (2010-02-02),
6. 7618964 - Benzamide derivatives, their manufacture and use as pharmaceutical agents (2009-11-17),
7. 7550589 - 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors (2009-06-23),
8. 7494993 - Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents (2009-02-24),
9. 7393936 - Method for the recombinant production and purification of protein kinases (2008-07-01),
10. 7214532 - Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof (2007-05-08),
11. 7189732 - Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives (2007-03-13),
12. 7186529 - Preparation of erythropoietin by endogenous gene activation (2007-03-06),
13. 7169781 - Imidazole derivatives and their use as pharmaceutical agents (2007-01-30),
14. 7163941 - Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents (2007-01-16),
15. 7091345 - Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives (2006-08-15),

Title: **Konrad Honold: Innovator in Protein Kinase Inhibitors**

Introduction

Konrad Honold is a prominent inventor based in Penzberg, Germany. With an impressive portfolio of 24 patents, his work primarily focuses on the development of innovative compounds for therapeutic applications. His notable contributions have significantly advanced the field of pharmaceutical science.

Latest Patents

Honold's latest patents are groundbreaking in their approach to treating illnesses such as cancer. One of his patents includes the development of imidazo[4,5-b]pyridine and pyrrolo[2,3-b]pyridine protein kinase inhibitors. This invention comprises compounds of specific formulas, including their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers, and racemates. These compounds are pivotal in the preparation of medicaments aimed at controlling or preventing illnesses like cancer.

Another noteworthy patent by Honold revolves around 7H-pyrido[3,4-d]pyrimidin-8-ones. Similar to his previous work, this invention details the manufacture and utility of these compounds as protein kinase inhibitors, focusing again on their therapeutic potential against cancer.

Career Highlights

Throughout his career, Honold has made substantial advancements in medicinal chemistry. His expertise has been honed through his associations with leading companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Roche Diagnostics GmbH. These affiliations have allowed him to collaborate on numerous projects that push the boundaries of medical research and innovation.

Collaborations

Konrad Honold has had the privilege of working alongside distinguished colleagues such as Stefan Scheiblich and Wolfgang Schaefer. Their collective efforts in research and development have been instrumental in the creation of innovative treatment options, particularly in the realm of cancer therapies.

Conclusion

Konrad Honold stands out as a significant figure in the landscape of pharmaceutical inventions. His extensive portfolio of patents showcases his commitment to developing effective solutions for challenging health issues. With a dedicated career built on collaboration and innovation, Honold continues to inspire future advancements in medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…